Obstructive sleep apnea in late-onset Pompe disease treated by enzyme replacement therapy

被引:2
|
作者
Bhui, Raj [1 ]
Spector, Andrew R. [1 ]
机构
[1] Duke Univ, Med Ctr, Dept Neurol, DUMC 3824, Durham, NC 27710 USA
关键词
Pompe disease; Neuromuscular disease; Obstructive Sleep Apnea; Enzyme Replacement Therapy; MYASTHENIA-GRAVIS;
D O I
10.1016/j.nmd.2020.02.004
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Obstructive sleep apnea is a common complication of Pompe disease. Treatment for obstructive sleep apnea in patients with Pompe disease is similar to treatment in the general population, typically involving positive airway pressure therapy. We present a case in which a patient with late-onset Pompe disease was able to discontinue positive airway pressure therapy after treatment with enzyme replacement therapy for his Pompe disease. It is likely that an improvement in muscle tone from the enzyme replacement therapy was sufficient to eliminate his obstructive sleep apnea. Pharmacological therapies for obstructive sleep apnea are lacking but could apply to certain populations, such as Pompe disease. (C) 2020 Elsevier B.V. All rights reserved.
引用
收藏
页码:329 / 330
页数:2
相关论文
共 50 条
  • [31] Clinical course of seven patients with late-onset Pompe disease receiving enzyme replacement therapy
    Spranger, M.
    Grunert, B.
    CLINICAL THERAPEUTICS, 2007, 29 : S120 - S121
  • [32] First case of a patient with late-onset Pompe disease: Cardiomyopathy remission with enzyme replacement therapy
    Ceron-Rodriguez, Magdalena
    Zamora, Antonio
    Erdmenger, Julio
    Urena, Roberto
    Consuelo Sanchez, Alejandra
    BOLETIN MEDICO DEL HOSPITAL INFANTIL DE MEXICO, 2014, 71 (01): : 41 - 46
  • [33] Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease
    Moriggi, Manuela
    Capitanio, Daniele
    Torretta, Enrica
    Barbacini, Pietro
    Bragato, Cinzia
    Sartori, Patrizia
    Moggio, Maurizio
    Maggi, Lorenzo
    Mora, Marina
    Gelfi, Cecilia
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (06) : 1 - 20
  • [34] Prognostic factors for late-onset Pompe disease with enzyme replacement therapy: The two sides of low BMI
    Ravaglia, Sabrina
    Carlucci, Annalisa
    Danesino, Cesare
    MOLECULAR GENETICS AND METABOLISM, 2010, 100 (04) : 388 - 388
  • [35] Initial therapeutic response to enzyme replacement therapy with Myozyme® in a sibling cohort with late-onset Pompe disease
    Hughes, D. S.
    Norwood, F.
    Sawicka, E.
    Milligan, A.
    Pringle, S.
    Bruce, R.
    Goodwin, S.
    Jennings, A.
    Richfield, L.
    Mehta, A. B.
    CLINICAL THERAPEUTICS, 2008, 30 : S29 - S30
  • [36] Functional capacity in a late-onset Pompe disease patient: Effect of enzyme replacement therapy and exercise training
    Krase, Argyro A.
    Papadimas, Giorgos K.
    Terzis, Gerasimos D.
    ANNALS OF INDIAN ACADEMY OF NEUROLOGY, 2016, 19 (03) : 423 - U136
  • [37] Early signs of benefit in a child with late-onset Pompe disease after treatment with enzyme replacement therapy
    Lianou, D.
    Syrengelas, D.
    Poulopoulos, P.
    Klimentopoulou, A.
    Mavridou, I.
    Michelakakis, H.
    CLINICAL THERAPEUTICS, 2007, 29 : S121 - S121
  • [38] Long-term effects of enzyme replacement therapy in an elderly cohort of late-onset Pompe disease
    Winkler, Maren
    von Landenberg, Christina
    Kuchenbecker, Katharina
    Reimann, Jens
    Kornblum, Cornelia
    NEUROMUSCULAR DISORDERS, 2022, 32 (03) : 195 - 205
  • [39] Enzyme replacement therapy induces T-cell responses in late-onset Pompe's disease
    Banati, M.
    Hosszu, Z.
    Trauninger, A.
    Szereday, L.
    Illes, Z.
    JOURNAL OF NEUROLOGY, 2011, 258 : 253 - 253
  • [40] Two cases of late-onset Pompe disease treated with enzyme replacement therapy: Clinical outcome for 3 years follow-up
    Lee, J. H.
    Cho, Y. N.
    Park, H. J.
    Choi, Y. C.
    NEUROMUSCULAR DISORDERS, 2014, 24 (9-10) : 871 - 871